Five years into his treatment for multiple myeloma, Mark Young was attending a Dana-Farber conference to learn about the latest research in the disease when his oncologist — Paul Richardson, MD, clinical program leader and director of clinical research at the Institute’s Jerome Lipper Multiple Myeloma Center — came running up with some timely news. … Continued
For many years, Thomas Palayoor and his wife, Sanjeewani, were engaged in cancer research in India. Inspired by the revolutionary advances being made in the biomedical field in the United States, they decided to move to the U.S. in 1978. Working at the medical schools of Ohio State University and Yale University, Palayoor branched off … Continued
Many sports stars have helped support research and care at Dana-Farber by appearing on the WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance Foundation, but few have done so quite like pro football wide receiver-turned-broadcaster Jimmy Cefalo. When Cefalo was interviewed on-air during the August 2019 event at Fenway Park, he used the opportunity to share some … Continued
Earlier this year, a novel drug became the first agent to receive U.S. Food and Drug Administration (FDA) approval for patients with multiple myeloma who have exhausted all types of currently available therapies, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies. A clinical trial found that 26.2 percent of such patients responded with significant shrinkage … Continued
In a surprising rebuttal of previous findings, a new study shows that African Americans with multiple myeloma have an overall higher survival rate than Caucasians with the disease when all patients have equal access to cutting-edge therapies. The results raise questions about the biology of this type of cancer. Multiple myeloma, a cancer that arises … Continued
In 2011, Diane Dike, PhD, lost her mother to complications from multiple myeloma — a cancer of the bone marrow involving plasma cells. The pair were always close, and even share the same birthday: October 23. The illness and death of her mother was extremely difficult for the whole family, Dike says. One of the most … Continued
Many of the immunotherapy drugs that are transforming the treatment of certain types of cancer are based on antibodies — artificial proteins that latch onto a molecular target, called an antigen. Bispecific antibodies, which can bind to two antigens at the same time, are being tested and moving toward clinical use in some blood cancers. … Continued
The process of converting genetic information from DNA to RNA, known as transcription, is a joint undertaking. Sections of DNA, known as promoters, collaborate with other sections known as enhancers to recast the genetic code into a form that can be used by cells to make proteins. As with many partnerships, however, it hasn’t been … Continued
Russ Horn went to work every day as a firefighter for almost 30 years. But now he has a new job—one that takes the same courage, hard work, and perseverance required in his last role. In 2014, Horn, then 50, was diagnosed with multiple myeloma—a cancer of plasma cells—after a minor slip at work sent … Continued
As father and daughter, there are many things Dennis Gorden and Becky Nutley share: a contagious smile, the instinct to help others, and a commitment to family, to name a few. But one thing they never imagined they would have in common was a cancer diagnosis. In 2014, routine blood work revealed that Becky Nutley, … Continued
As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and researchers face a new challenge: how to predict a drug’s long-term effectiveness? How to tell, early on, whether one drug is likely to extend patients’ lives more than another? At Dana-Farber’s Jerome Lipper … Continued
A study by Dana-Farber scientists and an international team of researchers could lead to better treatments for patients with smoldering multiple myeloma, a condition that often precedes myeloma.
Advances against multiple myeloma have come at an especially rapid pace, with 10 new therapies approved in just the last 10 years. As a group, their impact “is greater than anything we’ve seen in myeloma,” says Nikhil Munshi, MD, director of Basic and Correlative Science at Dana-Farber’s Jerome Lipper Center for Multiple Myeloma.
A year ago, Kelly Lamphere’s multiple myeloma was not responding to treatment, and her legs were so weakened by the cancer in her bones that she relied on a wheelchair and a walker. Today, because of CAR T-cell therapy, Lamphere’s disease is under control—and she can walk unaided again.
Assessing a multiple myeloma patient’s predicted outcome and risk through genetic analysis can enable tailored treatment for individual patients.
Minimal residual disease negativity – or MRD negativity – is a highly sensitive measure of the effectiveness of therapy for multiple myeloma, a cancer of plasma cells of the bone marrow.
“A caregiver and a patient are a team, like a coach and a quarterback,” says caregiver Deb Osborne. “You do a lot of work strategizing together beforehand, and then as the coach you send your quarterback into the action.
People diagnosed with precursor conditions that often lead to multiple myeloma currently have little way of gauging their risk of myeloma or knowing when, if ever, the disease might progress.
CAR T-cell therapy is a cancer treatment in which a patient’s immune system T cells are genetically modified to mount a more effective attack on cancer. As of May 2018, CAR T-cell therapy has been approved by the U.S. Food and Drug Administration as standard therapy for some adult patients with aggressive non-Hodgkin lymphoma that has relapsed after … Continued